Molecular Oncology
Volume 3, Issue 1 , Pages 33-44 , February 2009

Targeted proteomic strategy for clinical biomarker discovery

  • Ralph Schiess

      Affiliations

    • Institute of Molecular Systems Biology, ETH Zurich, Switzerland
    • Ph.D. Program in Molecular Life Science, University of Zurich, Switzerland
    • ,
  • Bernd Wollscheid

      Affiliations

    • Institute of Molecular Systems Biology, ETH Zurich, Switzerland
    • NCCR Neuro Center for Proteomics, ETH and University of Zurich, Switzerland
    • ,
  • Ruedi Aebersold

      Affiliations

    • Institute of Molecular Systems Biology, ETH Zurich, Switzerland
    • Institute for Systems Biology, Seattle, WA 98103, USA
    • Faculty of Science, University of Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Institute of Molecular Systems Biology, ETH Zurich, Switzerland.

Received 13 October 2008 ,Revised 1 December 2008 ,Accepted 2 December 2008.

References 

  1. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am. J. Hum. Genet. 2001;69:936–950
  2. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 2002;1:845–867
  3. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 2007;389:1017–1031
  4. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825–2831
  5. Bayer EA, Ben-Hur H, Wilchek M. Biocytin hydrazide–a selective label for sialic acids, galactose, and other sugars in glycoconjugates using avidin-biotin technology. Anal. Biochem. 1988;170:271–281
  6. Brand J, Haslberger T, Zolg W, Pestlin G, Palme S. Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics. 2006;6:3236–3242
  7. Celis JE, Gromov P, Cabezón T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell Proteomics. 2004;3:327–344
  8. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–369
  9. Chen EI, Yates JR. Cancer proteomics by quantitative shotgun proteomics. Mol. Oncol. 2007;1:144–159
  10. Christensen E, Evans KR, Ménard C, Pintilie M, Bristow RG. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Rev. 2008;375–385
  11. Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001;21:1465–1470
  12. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling – a young technology begins to mature. Nat. Biotechnol. 2005;23:291–292
  13. Desiere F, Deutsch EW, Nesvizhskii AI, Mallick P, King NL, Eng JK, et al Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Genome Biol. 2005;6:R9
  14. Deutsch EW, Eng JK, Zhang H, King NL, Nesvizhskii AI, Lin B, et al. Human plasma PeptideAtlas. Proteomics. 2005;5:3497–3500
  15. Deutsch EW, Lam H, Aebersold RH. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008;9:429–434
  16. Domon B, Aebersold RH. Challenges and opportunities in proteomics data analysis. Mol. Cell Proteomics. 2006;5:1921–1926
  17. Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics. 2005;5:3292–3303
  18. Eriksson J, Fenyö D. Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs. Nat. Biotechnol. 2007;25:651–655
  19. Flocks RH, Urich VC, Patel CA, Opitz JM. Studies on the antigenic properties of prostatic tissue. I. J. Urol. 1960;84:134–143
  20. Gahmberg CG, Tolvanen M. Why mammalian cell surface proteins are glycoproteins. Trends Biochem. Sci. 1996;21:308–311
  21. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 1992;23:273–279
  22. Goncalves A, Borg J, Pouyssegur J. Biomarkers in cancer management: a crucial bridge toward personalized medicine. Drug Discov. Today: Ther. Strategies. 2004;1:305–311
  23. Gravett MG, Thomas A, Schneider KA, Reddy AP, Dasari S, Jacob T, et al Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J. Proteome Res. 2007;6:89–96
  24. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer. 2006;6:565–571
  25. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold RH. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999;17:994–999
  26. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of “-seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi. 1971;25:322–324
  27. Herrmann W, Stöckle M, Sand-Hill M, Hübner U, Herrmann M, Obeid R, et al. The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen. Clin. Chem. Lab. Med. 2004;42:1051–1057
  28. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004;64:5504–5510
  29. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004;306:640–643
  30. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell Proteomics. 2005;4:1265–1272
  31. Issaq HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis. 2002;23:3048–3061
  32. Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev. Proteomics. 2004;1:49–55
  33. Janzi M, Odling J, Pan-Hammarstrom Q, Sundberg M, Lundeberg J, Hammarstrom L, et al. Serum microarrays for large scale screening of protein levels. Mol. Cell. Proteomics. 2005;4:1942–1947
  34. Jones H. On a new substance occurring in the urine of a patient with mollities ossium. Philosophical Transactions of the Royal Society of London (1776–1886). 2006;138:55–62
  35. Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin. Chem. 2006;52:1510–1515
  36. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild BC. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004;4:1175–1186
  37. Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, et al. Discovery of cancer biomarkers through the use of mouse models. Cancer Lett. 2007;249:40–48
  38. Kuster B, Schirle M, Mallick P, Aebersold RH. Scoring proteomes with proteotypic peptide probes. Nat. Rev. Mol. Cell Biol. 2005;6:577–583
  39. Kyle RA. Multiple myeloma: how did it begin?. Mayo Clin. Proc. 1994;69:680–683
  40. Lange V, Malmstrom JA, Didion J, King NL, Johansson BP, Schäfer J, et al Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol. Cell Proteomics. 2008;7:1489–1500
  41. Lange V, Picotti P, Domon B, Aebersold RH. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008;4:222
  42. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science. 2002;295:1898–1901
  43. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 2006;116:26–30
  44. Listgarten J, Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol. Cell Proteomics. 2005;4:419–434
  45. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004;76:4193–4201
  46. Loch C, Ramirez A, Liu Y, Sather C, Delrow J, Scholler N, et al. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol. Oncol. 2007;1:313–320
  47. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer. 2005;5:845–856
  48. Luftner D, Lüke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin. Biochem. 2003;36:233–240
  49. Mallick P, Schirle M, Chen SS, Flory MR, Lee H, Martin DB, et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat. Biotechnol. 2007;25:125–131
  50. Molloy MP, Brzezinski EE, Hang J, McDowell MT, VanBogelen RA. Overcoming technical variation and biological variation in quantitative proteomics. Proteomics. 2003;3:1912–1919
  51. Mueller LN, Brusniak MY, Mani DR, Aebersold RH. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J. Proteome Res. 2008;7:51–61
  52. Mueller LN, Rinner O, Schmidt A, Letarte S, Bodenmiller B, Brusniak MY, et al. SuperHirn – a novel tool for high resolution LC–MS-based peptide/protein profiling. Proteomics. 2007;7:3470–3480
  53. Staging: questions and answers, 2004. National Cancer Institute Fact Sheet 5.32.
  54. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. U S A. 2005;102:10852–10857
  55. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 2005;95:545–548
  56. Paik S, Shak S, Tang G, Kim C, Baker JO, Cronin M, et al A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004;351:2817–2826
  57. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  58. Picotti P, Lam H, Campbell D, Deutsch EW, Mirzaei H, Ranish J, et al. A database of mass spectrometric assays for the yeast proteome. Nat. Methods. 2008;5:913–914
  59. Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, et al Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J. Proteome Res. 2008;7:1481–1489
  60. Polanski M, Anderson NL. Candidate cancer markers. Biomarker Insights. 2006;2:1–48
  61. Pritzker KP. Cancer biomarkers: easier said than done. Clin. Chem. 2002;48:1147–1150
  62. Putnam FW. The trace components of plasma: an overview. Prog. Clin. Biol. Res. 1976;5:1–24
  63. Radulovic D, Jelveh S, Ryu S, Hamilton TG, Foss E, Mao Y, et al. Informatics platform for global proteomic profiling and biomarker discovery using liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics. 2004;3:984–997
  64. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101:5–10
  65. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006;24:971–983
  66. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513–516
  67. Schiess, R., Mueller, L.N., Schmidt, A., Mueller, M., Wollscheid, B., Aebersold, R.H., 2008. Analysis of cell surface proteome changes via label-free, quantitative mass spectrometry. Mol. Cell Proteomics, in press, doi: 10.1074/mcp.M800172-MCP200.
  68. Sinclair D, Dagg JH, Smith JG, Stott DI. The incidence and possible relevance of Bence-Jones protein in the sera of patients with multiple myeloma. Br. J. Haematol. 1986;62:689–694
  69. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  70. Soltermann A, Ossola R, Kilgus-Hawelski S, Von Eckardstein A, Suter T, Aebersold RH, et al. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer. 2008;114:124–133
  71. Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem. 2002;48:1160–1169
  72. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold RH, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell Proteomics. 2007;6:1809–1817
  73. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987;317:909–916
  74. States DJ, Omenn GS, Blackwell TW, Fermin D, Eng J, Speicher DW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 2006;24:333–338
  75. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park JH, et al Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. U S A. 2001;98:10787–10792
  76. Tang H, Arnold RJ, Alves P, Xun Z, Clemmer DE, Novotny MV, et al. A computational approach toward label-free protein quantification using predicted peptide detectability. Bioinformatics. 2006;22:e481–e488
  77. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7:230–240
  78. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl. Cancer Inst. 2006;98:1128–1133
  79. Tian Y, Zhou Y, Elliott S, Aebersold RH, Zhang H. Solid-phase extraction of N-linked glycopeptides. Nat. Protoc. 2007;2:334–339
  80. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193–197
  81. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  82. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347:1999–2009
  83. Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, et al Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007;6:3962–3975
  84. Wu, J. 2002 Circulating Tumor Markers of the New Millennium: Target Therapy, Early Detection, and Prognosis American Association for Clinical Chemistry.
  85. Yang Z, Hancock WS. Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J. Chromatogr. A. 2004;1053:79–88
  86. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat. Biotechnol. 2007;25:1119–1126
  87. Zhang H, Li XJ, Martin DB, Aebersold RH. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 2003;21:660–666
  88. Zhang H, Liu AY, Loriaux P, Wollscheid B, Zhou Y, Watts JD, et al. Mass spectrometric detection of tissue proteins in plasma. Mol. Cell Proteomics. 2007;6:64–71
  89. Zhang H, Loriaux P, Eng JK, Campbell DS, Keller A, Moss P, et al UniPep–a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol. 2006;7:R73
  90. Zhang H, Yi EC, Li XJ, Mallick P, Kelly-Spratt KS, Masselon CD, et al. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol. Cell Proteomics. 2005;4:144–155
  91. Zolg W. The proteomic search for diagnostic biomarkers: lost in translation?. Mol. Cell Proteomics. 2006;5:1720–1726

PII: S1574-7891(08)00151-8

doi: 10.1016/j.molonc.2008.12.001

Molecular Oncology
Volume 3, Issue 1 , Pages 33-44 , February 2009

Article Tools

* Image Usage & Resolution